Exempa Lin Met XR 12.5/2.5/1000mg Tablet — Triple Therapy for Type 2 Diabetes
Pay in 3 Installments of
Rs.
171
JazzCash
easypaisa
NayaPay
Bank transfer
Cash on Delivery
Description
Exempa Lin Met XR 12.5/2.5/1000mg Tablet is a fixed-dose triple combination containing Empagliflozin 12.5mg (SGLT2 inhibitor), Linagliptin 2.5mg (DPP-4 inhibitor), and Metformin HCl 1000mg XR (biguanide) — prescribed for adults with Type 2 Diabetes Mellitus requiring intensified glycaemic management.
Empagliflozin lowers blood glucose by promoting urinary glucose excretion and provides cardiovascular and renal protection. Linagliptin enhances glucose-dependent insulin secretion and reduces glucagon levels. Metformin XR decreases hepatic glucose production and improves insulin sensitivity — all in a single once-daily extended-release tablet.
For patients requiring a lower Empagliflozin dose, consider Exempa Lin Met XR 10/5/1000mg Tablet. For dual-component SGLT2+Metformin therapy, see Empaglimet 12.5/500mg Tablet.
Safety Information: Not for Type 1 diabetes or diabetic ketoacidosis. Contraindicated in severe renal impairment (eGFR <45). Monitor kidney function and blood glucose regularly. Rx only — valid prescription required. Email to sales@derma.pk or WhatsApp +92-320-5999650.
Usage & Benefits
- Triple-mechanism glycaemic control: SGLT2 inhibition + DPP-4 inhibition + biguanide action
- Reduces blood glucose without weight gain from insulin-independent SGLT2 excretion
- Enhances glucose-dependent insulin secretion via Linagliptin's DPP-4 inhibition
- Provides proven cardiovascular and renal protective benefits from Empagliflozin
- Convenient once-daily extended-release formulation reducing pill burden
How To Use
1. Take Exempa Lin Met XR once daily as prescribed by your doctor.
2. Swallow the tablet whole with a glass of water — do not crush or chew.
3. Take with the evening meal to reduce gastrointestinal side effects from Metformin.
4. Monitor blood glucose and kidney function (eGFR) regularly.
5. Do not stop or adjust the dose without consulting your physician.
6. Use only as directed by your healthcare provider.
FAQs
What makes Exempa Lin Met XR a triple therapy?
It combines three antidiabetic agents — Empagliflozin (SGLT2 inhibitor), Linagliptin (DPP-4 inhibitor), and Metformin XR (biguanide) — each acting through a different mechanism to lower blood sugar comprehensively.
Does the XR formulation make a difference?
Yes. The extended-release (XR) formulation ensures gradual release of Metformin throughout the day, improving tolerability and reducing gastrointestinal side effects compared to immediate-release formulations.
Can this tablet be used by patients with mild kidney disease?
Use with caution. It is contraindicated in patients with eGFR below 45 mL/min/1.73m². Your doctor will check your kidney function before prescribing and periodically during therapy.
